ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

BRIVIACT INJECTION
Seizure disorders
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

BRIVIACT INJECTION CV

Generic Name and Formulations:
Brivaracetam 50mg/5mL; soln for IV use; preservative-free.

Company:
UCB Inc.

Therapeutic Use:

Indications for BRIVIACT INJECTION:

Partial-onset seizures, as monotherapy or adjunctive treatment when oral administration is temporarily not feasible.

Adult:

Interchangeable with other forms. Give by IV over 2 to 15 minutes; limit to 4 consecutive days of treatment. ≥16yrs: initially 50mg twice daily; may adjust down to 25mg twice daily or up to 100mg twice daily based on response and tolerability. Hepatic impairment: initially 25mg twice daily; max 75mg twice daily. Concomitant rifampin: double brivaracetam dosage.

Children:

<16yrs: not established.

Warnings/Precautions:

Increased risk of suicidal behavior or ideation; monitor for clinical worsening and/or any unusual changes. Monitor for neurological and psychiatric adverse reactions. Discontinue if hypersensitivity reactions occur. Hepatic impairment: adjust dose (see Adult). End-stage renal disease undergoing dialysis: not recommended. Avoid abrupt cessation. Pregnancy. Nursing mothers.

Interactions:

Antagonized by rifampin (see Adult). Concomitant carbamazepine: may consider dose reduction if intolerant. May potentiate phenytoin; monitor phenytoin levels when adding or discontinuing brivaracetam from ongoing therapy. Concomitant levetiracetam: no added benefit.

See Also:

BRIVIACT

BRIVIACT ORAL SOLUTION

Pharmacological Class:

Antiepileptic.

Adverse Reactions:

Somnolence/sedation, dizziness, fatigue, nausea/vomiting; hematologic abnormalities.

Note:

To enroll in the North American Antiepileptic Drug Pregnancy Registry call (888) 233-2334.

Generic Availability:

NO

How Supplied:

Tabs—60; Oral soln—300mL; Single-dose vials—10

Sign Up for Free e-Newsletters